FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W47695062> ?p ?o ?g. }

• W47695062 endingPage "9" @default.
• W47695062 startingPage "415" @default.
• W47695062 abstract "To analyze and summarize the characteristics of glycogen storage disease type II (Pompe disease) patients according to the clinical description and prognosis.Seventeen Chinese patients diagnosed by acid alpha-glucosidase (GAA) enzyme activity test were reviewed. Clinical data tables were designed. Interviews were made via phone calls. Information was collected to reach the objective.Four of 17 patients diagnosed by acid alpha-glucosidase are infantile-onset, symptoms started between 2 to 6 months after birth with increased serum creatine kinase and cardiac problems, with or without respiratory concerns. Other 13 patients were later-onset cases, and their symptoms started between 2 to 22 years of age with increased serum creatine kinase. Eleven later-onset patients started with muscle weakness, 2 patients developed respiratory insufficiency, 2 patients showed scoliosis, and 1 patient expressed increased serum creatine kinase with abnormal liver function. Just 3 of the later-onset patients were treated with mechanical ventilator and adjuvant therapy, others were not. All patients' acid alpha-glucosidase (GAA) enzyme activity analysis showed lower than 10% of normal. Fourteen patients were tested by muscle biopsy pathology, and 9 of them progressed to glycogen storage disease type II; 10 patients received genetic analysis, and 6 of them had two mutations which cause the disorder. Twelve of the 17 patients were interviewed successfully. In 3 of the infant-onset patients the disease resulted in death from respiratory failure, and 1 is still alive at the age of 1 year and 7 months. In 4 of 8 later-onset patients the disease resulted in death from respiratory failure between 3 to 5 years after onset of symptoms. Three of 4 survivors had increased muscle weakness, and 1 patient kept alive with ventilator without any changes. Seven of 12 interviewed patients died, the mortality rate was 58.3%.Glycogen storage disease type II (Pompe disease) present differently in the clinic. Infant-onset Pompe disease is mainly characterized by generalized muscle weakness and obvious cardiac involvement. It's a dangerous disease, with high mortality rate. Later-onset Pompe disease is characterized by chronic proximal muscle weakness and respiratory insufficiency. GAA enzyme activity analysis, muscle biopsy and genetic analysis used to support the diagnosis of Pompe disease. Prognosis of the disease depends on age of onset and respiratory muscle involvement." @default.
• W47695062 created "2016-06-24" @default.
• W47695062 creator A5014963018 @default.
• W47695062 creator A5050527989 @default.
• W47695062 creator A5052851627 @default.
• W47695062 creator A5066913542 @default.
• W47695062 creator A5076555646 @default.
• W47695062 date "2012-06-01" @default.
• W47695062 modified "2023-09-25" @default.
• W47695062 title "[Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease]." @default.
• W47695062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22931935" @default.
• W47695062 hasPublicationYear "2012" @default.
• W47695062 type Work @default.
• W47695062 sameAs 47695062 @default.
• W47695062 citedByCount "1" @default.
• W47695062 countsByYear W476950622015 @default.
• W47695062 crossrefType "journal-article" @default.
• W47695062 hasAuthorship W47695062A5014963018 @default.
• W47695062 hasAuthorship W47695062A5050527989 @default.
• W47695062 hasAuthorship W47695062A5052851627 @default.
• W47695062 hasAuthorship W47695062A5066913542 @default.
• W47695062 hasAuthorship W47695062A5076555646 @default.
• W47695062 hasConcept C126322002 @default.
• W47695062 hasConcept C141071460 @default.
• W47695062 hasConcept C187212893 @default.
• W47695062 hasConcept C2776888751 @default.
• W47695062 hasConcept C2779134260 @default.
• W47695062 hasConcept C2779969927 @default.
• W47695062 hasConcept C36880943 @default.
• W47695062 hasConcept C71924100 @default.
• W47695062 hasConcept C90924648 @default.
• W47695062 hasConceptScore W47695062C126322002 @default.
• W47695062 hasConceptScore W47695062C141071460 @default.
• W47695062 hasConceptScore W47695062C187212893 @default.
• W47695062 hasConceptScore W47695062C2776888751 @default.
• W47695062 hasConceptScore W47695062C2779134260 @default.
• W47695062 hasConceptScore W47695062C2779969927 @default.
• W47695062 hasConceptScore W47695062C36880943 @default.
• W47695062 hasConceptScore W47695062C71924100 @default.
• W47695062 hasConceptScore W47695062C90924648 @default.
• W47695062 hasIssue "6" @default.
• W47695062 hasLocation W476950621 @default.
• W47695062 hasOpenAccess W47695062 @default.
• W47695062 hasPrimaryLocation W476950621 @default.
• W47695062 hasRelatedWork W1914211225 @default.
• W47695062 hasRelatedWork W2051801495 @default.
• W47695062 hasRelatedWork W2055601045 @default.
• W47695062 hasRelatedWork W2348809255 @default.
• W47695062 hasRelatedWork W2402487766 @default.
• W47695062 hasRelatedWork W2415456991 @default.
• W47695062 hasRelatedWork W3216506977 @default.
• W47695062 hasRelatedWork W4233056928 @default.
• W47695062 hasRelatedWork W47695062 @default.
• W47695062 hasRelatedWork W2191850086 @default.
• W47695062 hasVolume "50" @default.
• W47695062 isParatext "false" @default.
• W47695062 isRetracted "false" @default.
• W47695062 magId "47695062" @default.
• W47695062 workType "article" @default.